Innovation is Crucial for Tackling Doubt in Biomanufacturing

Biologic drug substances are large, complex molecules prepared from living systems via complex cell-culture or fermentation processes. Given this complexity, it can be difficult to achieve consistent and predictable performance, with numerous factors from raw material variability to operator training to equipment selection influencing process outcomes. BioPharm International explored a number of new manufacturing technologies and approaches to improve process robustness and enhance product consistency and quality, including increased collaboration with multifunctional teams, process analytical technology (PAT) and automation systems, the adoption of single-use equipment, and more (1).

This topic and and other related issues will be addressed at bioLIVE, launching alongside CPhI Worldwide 2018 in Madrid, Spain, from Oct. 9–11, 2018. Events include a keynote by Eric Langer, president and managing partner, BioPlan Associates, exploring ‘Introduction to Biopharmaceuticals-Setting the Scene’ on Tuesday, Oct. 9, 2018, 10:30–11:00am. There will alsobe a panel discussion on continuous manufacturing featuring John Liddell, senior scientific advisor, The Centre for Process Innovation; Craig Johnston, industry director, CMAC; and Maria Agustina Duguine, owner, Global Regulatory Affairs and Consulting and professor BA chemistry, UB University Argentina, taking place on Tuesday, Oct. 9, 2018, 11:00am–12:00pm.

Learn more at bioLIVE, an exhibition and conference for biopharmaceutical development and manufacturing which is launching this year adjacent to CPhI Worldwide. bioLIVE is a new specialized event focusing on large-molecule biopharma and-more specifically-on manufacturing and processing within the industry.

Reference

1. C. Challener, BioPharm International, 31 (5) 2018.